Amylyx Phase 3 Results Show Avexitide Cut Hypoglycemia
Amylyx Phase 3 Results show avexitide met LUCIDITY endpoints and the company signaled a year-end NDA plan that shifts trader positioning.
KEY TAKEAWAYS
- LUCIDITY Phase 3 met the FDA-agreed primary endpoint with avexitide reducing composite Level 2 and 3 events 55%
- Amylyx plans an NDA submission to the FDA by year-end 2026, advancing regulatory review
- Avexitide holds Breakthrough Therapy and Orphan Drug designations, supporting an accelerated approval pathway
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Amylyx Pharmaceuticals released Phase 3 results on Aug. 18, 2026, showing it will pursue U.S. approval after positive topline data for avexitide in post-bariatric hypoglycemia, a condition without FDA-approved therapies.
LUCIDITY Trial Results and Safety Profile
Amylyx said in a press release on Aug. 18, 2026, that LUCIDITY was a 78-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial in adults with post-bariatric hypoglycemia following Roux-en-Y gastric bypass surgery. The investigational drug, avexitide, is a first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist.
The company reported that LUCIDITY met the FDA-agreed primary endpoint, showing a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared with placebo (p=0.000003). All secondary endpoints were also met, including reductions in Level 2 hypoglycemic events measured by self-monitoring of blood glucose and continuous glucose monitoring, as well as Level 3 severe hypoglycemic events. These reductions were consistent, highly statistically significant, and clinically meaningful.
Avexitide was described as generally well-tolerated with a favorable safety profile.
Regulatory Path and Company Plans
Amylyx said it will submit a New Drug Application (NDA) to the FDA by year-end 2026 for avexitide in post-bariatric hypoglycemia following Roux-en-Y gastric bypass, based on the LUCIDITY efficacy and safety data. The drug holds FDA Breakthrough Therapy and Orphan Drug designations for this indication.
On its Aug. 6, 2026 second-quarter earnings call, management said LUCIDITY was powered at 90% to detect a 35% treatment effect and that topline data were expected in late August or early September. The company has now moved from that planned readout to a formal filing timetable based on the results.
Post-bariatric hypoglycemia is a chronic metabolic condition characterized by recurrent low blood sugar after bariatric surgery, with no FDA-approved treatments. Amylyx’s planned NDA submission targets this orphan indication.
The immediate regulatory milestone is the NDA submission, advancing the program toward FDA review under the disclosed timetable.
